본문 바로가기
KERD
논문KCI 등재

Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance

이정언|유종한|박연희|박경희|김유진|박송이|이한상|임성원|안진석|조장호|김지연|임영혁|김희경
대한암학회 (Korean Cancer Association)|2019.04|Cancer Research and Treatment|제51권 제2호|pp. 737-747

3

조회

0

다운로드

0

인용

0

참고문헌

키워드

Breast neoplasmsImmunohistochemistryPAM50
주제분류의학일반

초록

Purpose We aimed to analyze the discordance between immunohistochemistry (IHC)-based surrogate subtyping and PAM50 intrinsic subtypes and to assess overall survival (OS) according to discordance. Materials and Methods A total of 607 patients were analyzed. Hormone receptor (HR) expression was evaluated by IHC, and human epidermal growth factor receptor 2 (HER2) expression was analyzed by IHC and/or fluorescence in situ hybridization. PAM50 intrinsic subtypes were determined according to 50 cancer genes using the NanoString nCounter Analysis System. We matched concordant tumor as luminal A and HR+/HER2–, luminal B and HR+/HER2+, HR–/HER2+ and HER2–enriched, and triple-negative breast cancer (TNBC) and normal- or basal-like. We used Ion Ampliseq Cancer Panel v2 was used to identify the genomic alteration related with discordance. The Kaplan-Meier method was used to estimate OS. Results In total, 233 patients (38.4%) were discordant between IHC-based subtype and PAM50 intrinsic subtype. Using targeted sequencing, we detected somatic mutation–related discordant breast cancer including the VHL gene in the HR+/HER2– group (31% in concordant group, 0% in discordant group, p=0.03) and the IDH and RET genes (7% vs. 12%, p=0.02 and 0% vs. 25%, p=0.02, respectively) in the TNBC group. Among the luminal A/B patients with a discordant result had significantly worse OS (median OS, 73.6 months vs. not reached; p < 0.001), and among the patients with HR positivity, the basal-like group as determined by PAM50 showed significantly inferior OS compared to other intrinsic subtypes (5-year OS rate, 92.2% vs. 75.6%; p=0.01). Conclusion A substantial portion of patients showed discrepancy between IHC subtype and PAM50 intrinsic subtype in our study. The survival analysis demonstrated that current IHC-based classification could mislead the treatment and result in poor outcome. Current guidelines for IHC might be updated accordingly.

Abstract

Purpose We aimed to analyze the discordance between immunohistochemistry (IHC)-based surrogate subtyping and PAM50 intrinsic subtypes and to assess overall survival (OS) according to discordance. Materials and Methods A total of 607 patients were analyzed. Hormone receptor (HR) expression was evaluated by IHC, and human epidermal growth factor receptor 2 (HER2) expression was analyzed by IHC and/or fluorescence in situ hybridization. PAM50 intrinsic subtypes were determined according to 50 cancer genes using the NanoString nCounter Analysis System. We matched concordant tumor as luminal A and HR+/HER2–, luminal B and HR+/HER2+, HR–/HER2+ and HER2–enriched, and triple-negative breast cancer (TNBC) and normal- or basal-like. We used Ion Ampliseq Cancer Panel v2 was used to identify the genomic alteration related with discordance. The Kaplan-Meier method was used to estimate OS. Results In total, 233 patients (38.4%) were discordant between IHC-based subtype and PAM50 intrinsic subtype. Using targeted sequencing, we detected somatic mutation–related discordant breast cancer including the VHL gene in the HR+/HER2– group (31% in concordant group, 0% in discordant group, p=0.03) and the IDH and RET genes (7% vs. 12%, p=0.02 and 0% vs. 25%, p=0.02, respectively) in the TNBC group. Among the luminal A/B patients with a discordant result had significantly worse OS (median OS, 73.6 months vs. not reached; p < 0.001), and among the patients with HR positivity, the basal-like group as determined by PAM50 showed significantly inferior OS compared to other intrinsic subtypes (5-year OS rate, 92.2% vs. 75.6%; p=0.01). Conclusion A substantial portion of patients showed discrepancy between IHC subtype and PAM50 intrinsic subtype in our study. The survival analysis demonstrated that current IHC-based classification could mislead the treatment and result in poor outcome. Current guidelines for IHC might be updated accordingly.

참고문헌 (30)

  1. Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
  2. Cancer Genome Atlas Network, "Comprehensive molecular portraits of human breast tumours", Nature, 490, pp.61~70 (2012)
  3. Perou CM, "Molecular portraits of human breast tumours", Nature, 406, pp.747~752 (2000)
  4. Prat A, "PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer", Breast Cancer Res Treat, 135, pp.301~306 (2012)
  5. Sotiriou C, "Gene-expression signatures in breast cancer", N Engl J Med, 360, pp.790~800 (2009)
  6. Paik S, "A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer", N Engl J Med, 351, pp.2817~2826 (2004)
  7. Parker JS, "Supervised risk predictor of breast cancer based on intrinsic subtypes", J Clin Oncol, 27, pp.1160~1167 (2009)
  8. Prat A, "Deconstructing the molecular portraits of breast cancer", Mol Oncol, 5, pp.5~23 (2011)
  9. Gnant M, "Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk : using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone", Ann Oncol, 25, pp.339~345 (2014)
  10. Dowsett M, "Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy", J Clin Oncol, 31, pp.2783~2790 (2013)
  11. Nielsen TO, "A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer", Clin Cancer Res, 16, pp.5222~5232 (2010)
  12. Leong SP, "Is breast cancer the same disease in Asian and Western countries?", World J Surg, 34, pp.2308~2324 (2010)
  13. 민선영, "The Basic Facts of Korean Breast Cancer in 2013: Results of a Nationwide Survey and Breast Cancer Registry Database", Journal of Breast Cancer, 19(1), pp.1~7 (2016), 한국유방암학회
  14. Park YH, "Prevalence and clinical outcomes of young breast cancer(YBC)patients according to intrinsic breast cancer subtypes : Single institutional experience in Korea", Breast, 24, pp.213~217 (2015)
  15. Harris LN, "Use of biomarkers to guide decisions on adjuvant systemic therapy for women with earlystage invasive breast cancer : American Society of Clinical Oncology clinical practice guideline", J Clin Oncol, 34, pp.1134~1150 (2016)
  16. Sohn I, "Gradient lasso for Cox proportional hazards model", Bioinformatics, 25, pp.1775~1781 (2009)
  17. Johnson WE, "Adjusting batch effects in microarray expression data using empirical Bayes methods", Biostatistics, 8, pp.118~127 (2007)
  18. Goldhirsch A, "Personalizing the treatment of women with early breast cancer : highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013", Ann Oncol, 24, pp.2206~2223 (2013)
  19. Krop I, "Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer : American Society of Clinical Oncology clinical practice guideline focused update", J Clin Oncol, 35, pp.2838~2847 (2017)
  20. Goldhirsch A, "Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011", Ann Oncol, 22, pp.1736~1747 (2011)
  21. Paquet ER, "Absolute assignment of breast cancer intrinsic molecular subtype", J Natl Cancer Inst, 107, pp.357~ (2015)
  22. Carey LA, "Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib", J Clin Oncol, 34, pp.542~549 (2016)
  23. Ramaswamy S, "A molecular signature of metastasis in primary solid tumors", Nat Genet, 33, pp.49~54 (2003)
  24. van 't Veer LJ, "Gene expression profiling predicts clinical outcome of breast cancer", Nature, 415, pp.530~536 (2002)
  25. Parsons DW, "An integrated genomic analysis of human glioblastoma multiforme", Science, 321, pp.1807~1812 (2008)
  26. Combs SE, "Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?", Radiat Oncol, 6, pp.115~ (2011)
  27. Kan Z, "Diverse somatic mutation patterns and pathway alterations in human cancers", Nature, 466, pp.869~873 (2010)
  28. Plaza-Menacho I, "Current concepts in RET-related genetics, signaling and therapeutics", Trends Genet, 22, pp.627~636 (2006)
  29. Esseghir S, "A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET", GFR alpha 1 receptor up-regulation in breast cancer, 2007, pp.67, 11732~11741
  30. Tozlu S, "Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach", Endocr Relat Cancer, 13, pp.1109~1120 (2006)

관련 논문AI추천

Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome권영미, 김병남, 남병호, 노정실, 박인혜, 유지영, 이근석, 이무현, 이은숙, 정소연, Siew Kuan Lim대한암학회 · Cancer Research and Treatment2016 · 제48권 제1호Analysis of the molecular subtypes of preoperative core needle biopsy and surgical specimens in invasive breast cancer강준, 김성훈, 이아원, 이지은, 정예슬, YOO TAE KYUNG R대한병리학회 · Journal of Pathology and Translational Medicine2020 · 제54권 제1호Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer김석원, 김지연, 남석진, 박경희, 박연희, 배수연, 안진석, 이광희, 이세경, 이은진, 이정언, 임영혁, 정혜현, 조은윤대한암학회 · Cancer Research and Treatment2016 · 제48권 제4호Prognostic Performance of the Next-Generation Sequencing–Based Multigene Assay in Early Breast Cancer Patients Treated According to the 21-Gene Assay Results강병주, 강은혜, 고지원, 김범준, 류재민, 박웅기, 박지영, 손정은, 이새별, 이지연, 이한별, 이현우, 이희진, 정우성, 천종호, 한원식대한암학회 · Cancer Research and Treatment2025 · 제57권 제3호Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center StudyCaijin Lin, Chihwan Goh, Hui Wang, Jiahui Huang, Jianrong He, Jiayi Wu, Jin Hong, Kunwei Shen, Linling Yin, Lisa Andriani, Li Zhu, Ou Huang, Shuning Ding, Siji Zhu, Weiguo Chen, Weiqi Gao, Xiaochun Fei, Xiaosong Chen, Yafen Li대한암학회 · Cancer Research and Treatment2020 · 제52권 제3호Clinical Usefulness of a Multigene Testing in Patients with Special Histologic Type Breast Cancer박세호, 박정민, 안지현, 윤찬석, 이석준연세대학교의과대학 · Yonsei Medical Journal2025 · 제66권 제10호

이 간행물의 다른 논문 (40건)

In Memoriam: Waun Ki Hong, M.D. (August 13, 1942-January 2, 2019)김훈교pp. 415-416Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016정규원, 이은숙, 공현주, 원영주pp. 417-430Prediction of Cancer Incidence and Mortality in Korea, 2019정규원, 원영주, 공현주, 이은숙pp. 431-437Preclinical Efficacy of [V4Q5]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal CancerNatasha T. Sobol, Juan Garona, Giselle V. Ripoll, Daniel F. Alonso, Daniel E. Gomez, Valeria I. Segatori, Marina Pifanopp. 438-450Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells임지민, 김정은, 김성영, 이경훈, 오도연, 장혜민, 김소현, 하동현, 정원재, 서경진, 방영주, 임석아, 양예원, 민아름, 김태용, 이미소pp. 451-463
원문 보기